Horizon Therapeutics plc Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)

— If Approved, Teprotumumab Would be the First FDA-Approved Medicine for this Vision-Threatening Disease —